ReviewBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2009
Targeted therapies for malignant glioma: progress and potential.
Review in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Application of EGFR-TKIs in brain tumors, a breakthrough in future?Journal of translational medicine · 2025Review
- SAR study of niclosamide derivatives in the human glioblastoma U-87 MG cells.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2022Article
- The new oncogene transmembrane protein 60 is a potential therapeutic target in glioma.Frontiers in genetics · 2022Article
- miR-381-3p Involves in Glioma Progression by Suppressing Tumor-Promoter Factor ANTXR1.Computational and mathematical methods in medicine · 2021Article
- Expression and clinical significance ofInternational journal of clinical and experimental pathology · 2021Article
- Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas.Cancers · 2020Review
- Article
- ROS and Brain Gliomas: An Overview of Potential and Innovative Therapeutic Strategies.International journal of molecular sciences · 2016Review
- The challenges and the promise of molecular targeted therapy in malignant gliomas.Neoplasia (New York, N.Y.) · 2015Review
- Diagnostic and prognostic value of a disintegrin and metalloproteinase-17 in patients with gliomas.Oncology letters · 2014Article
- Combined efficacy of cediranib and quinacrine in glioma is enhanced by hypoxia and causally linked to autophagic vacuole accumulation.PloS one · 2014Article
- The unfolded protein response in glioblastomas: passing the stress test.CNS oncology · 2013Article
- PKC signaling in glioblastoma.Cancer biology & therapy · 2013Review
- The antiproliferative effect of indomethacin-loaded lipid-core nanocapsules in glioma cells is mediated by cell cycle regulation, differentiation, and the inhibition of survival pathways.International journal of nanomedicine · 2013Article
- The association of statins plus LDL receptor-targeted liposome-encapsulated doxorubicin increases in vitro drug delivery across blood-brain barrier cells.British journal of pharmacology · 2012Article
- Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling.Investigational new drugs · 2012Article
- Frontiers in Suicide Gene Therapy of Cancer.Journal of genetic syndromes & gene therapy · 2012Article
- A novel adenoviral vector labeled with superparamagnetic iron oxide nanoparticles for real-time tracking of viral delivery.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2012Article
- Decreased expression of the augmenter of liver regeneration results in increased apoptosis and oxidative damage in human-derived glioma cells.Cell death & disease · 2012Article
- Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Malignant gliomas represent one of the most aggressive forms of brain cancer. Recent advances in the understanding of the deregulated molecular pathways of gliomas have brought about targeted therapies that have the ability to increase therapeutic efficacy in tumors while decreasing toxicity. Multi-targeted kinase inhibitors, novel monoclonal antibodies, and new vaccines have been developed. Standard treatments and current development of new therapies for malignant gliomas are reviewed, focusing specifically on growth factors and their receptors (e.g. epidermal growth factor receptor, vascular endothelial growth factor receptor, and platelet-derived growth factor receptor), as well as the intracellular effector molecules that are downstream of these growth factors (e.g. Ras/Raf/mitogen-activated protein kinase, phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin, and protein kinase C). The efficacies of other novel targeted inhibitors such as deacetylase inhibitors and heat shock protein 90 inhibitors in the treatment of gliomas are also discussed, as well as new combination therapies. In order for new agents to increase treatment efficacy, new targets need to be developed, drug delivery efficiency needs to be improved, and new biomarkers need to be discovered. All of these goals can be accomplished with time through innovative experimental designs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.